• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Higher; Inflation Rate Increases To 3.4% In December

    1/11/24 9:44:55 AM ET
    $ATNF
    $BCEL
    $CMND
    $MLEC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Thursday.

    Following the market opening Thursday, the Dow traded up 0.07% to 37,723.53 while the NASDAQ rose 0.46% to 15,039.09. The S&P 500 also rose, gaining, 0.21% to 4,793.32.

    Check This Out: Top 5 Materials Stocks That Are Ticking Portfolio Bombs

     

    Leading and Lagging Sectors

     

    Information technology shares rose by 0.8% on Thursday.

    In trading on Thursday, utilities shares fell by 0.6%.

     

    Top Headline

     

    U.S. consumer prices increased by 0.3% month-over-month in December compared to a 0.1% rise in November and versus market estimates of 0.2%.

    The annual inflation rate rose to 3.4% in December versus a five-month low level of 3.1% in November, and compared to market estimates of 3.2%.

     

    Equities Trading UP

     

    Atreca, Inc. (NASDAQ:BCEL) shares shot up 95% to $0.2090 after falling around 7% on Wednesday. Atreca, last month, announced the sale of a collection of antibody-related assets and materials to Immunome consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones.

    Shares of Moolec Science SA (NASDAQ:MLEC) got a boost, surging 35% to $2.5850.

    Spectaire Holdings Inc. (NASDAQ:SPEC) shares were also up, gaining 27% to $3.0873. Spectaire signed a distribution agreement with MLab and Mosolf to bring AireCore Emissions System in Europe.

     

    Equities Trading DOWN

     

    Clearmind Medicine Inc. (NASDAQ:CMND) shares dropped 49% to $1.4799. Clearmind Medicine reported pricing of $2.4 million registered direct and private placement.

    Shares of YanGuFang International Group Co., Ltd. (NASDAQ:YGF) were down 36% to $1.1601. YanGuFang International named Ya Zhang Interim CEO and Yang Sui as Interim CFO, effective as of Jan. 9, 2024.

    180 Life Sciences Corp. (NASDAQ:ATNF) was down, falling 23% to $0.2330. 180 Life Sciences was granted EU patent titled "Method of Treating a Localized Fibrotic Disorder Using An Il-33 Antagonist."

    Also Check This Out: How To Earn $500 A Month From Citigroup Stock Ahead Of Q4 Earnings Report

     

    Commodities

     

    In commodity news, oil traded up 1.4% to $72.40 while gold traded up 0.2% at $2,031.10.

    Silver traded up 0.2% to $23.115 on Thursday while copper rose 0.5% to $3.7995.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.2%, London’s FTSE 100 fell 0.1% while Spain’s IBEX 35 Index rose 0.4% The German DAX rose 0.3% French CAC 40 rose 0.3% while Italy’s FTSE MIB Index rose 0.4%.

    Industrial production in Spain increased by 0.8% year-over-year in November, while Italy’s industrial production declined by 1.5% month-over-month in November.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Thursday, with Japan’s Nikkei 225 gaining 1.77%, Hong Kong’s Hang Seng Index rising 1.27% and China’s Shanghai Composite Index gaining 0.31%. India’s S&P BSE Sensex, meanwhile, rose 0.1%.

    China's vehicle sales jumped 23.5% year-over-year in December to 3.156 million units, following a 27.4% surge in November. The index of leading economic indicators in Japan fell to 107.7 in November versus a final reading of 108.9 in the earlier month, while index of coincident economic indicators fell to 114.5 in November compared to a final 115.9 a month ago. Reserve assets in Japan climbed to $1.295 trillion in December from $1.270 trillion a month ago, recording the highest level since July 2022.

     

    Economics

     

    U.S. consumer prices increased by 0.3% month-over-month in December compared to a 0.1% rise in November and versus market estimates of 0.2%.

    The annual inflation rate rose to 3.4% in December versus a five-month low level of 3.1% in November, and compared to market estimates of 3.2%.

    U.S. initial jobless claims declined by 1,000 from the prior week’s revised reading of 202,000 in the period ending Jan, 6, compared to market expectations of 210,000.

    Now Read This: Chewy To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Thursday

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $BCEL
    $CMND
    $MLEC

    CompanyDatePrice TargetRatingAnalyst
    Moolec Science SA
    $MLEC
    9/27/2023$5.00Buy
    ROTH MKM
    Atreca Inc.
    $BCEL
    3/4/2022$17.00 → $14.00Buy
    Stifel
    180 Life Sciences Corp.
    $ATNF
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    $BCEL
    $CMND
    $MLEC
    SEC Filings

    View All

    SEC Form F-3 filed by Clearmind Medicine Inc.

    F-3 - Clearmind Medicine Inc. (0001892500) (Filer)

    2/17/26 4:46:24 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    2/17/26 4:44:21 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Clearmind Medicine Inc.

    SCHEDULE 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)

    2/17/26 10:48:57 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CMND
    $MLEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Jordan Blair disposed of 200,000 shares (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/25/25 6:53:40 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Former 10% Owner Elray Resources, Inc. sold $9,278,586 worth of shares (2,998,000 units at $3.09) and exercised 3,000,000 in-the-money shares at a strike of $1.68, increasing direct ownership by 0.15% to 1,320,000 units (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/18/25 5:27:22 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Rudisill Mcandrew

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 5:20:03 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CMND
    $MLEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

    Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). These further safety data points, emerging following the successful completion of treatment in another six pati

    2/9/26 8:17:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

    Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into a development agreement with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind"), a clinical‑stage biopharmaceutical company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems. Under this agreement, Polyr

    2/6/26 7:55:00 AM ET
    $CMND
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

    Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind's lead MEAI candidate for addiction-related and other CNS disorders Vancouver, Canada, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a development agreement with Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon"), a pre-clinical-stage biotechnology company developing advanced intranasal delivery solutions. Under the agreement, Clear

    2/6/26 7:55:00 AM ET
    $CMND
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CMND
    $MLEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ATNF
    $BCEL
    $CMND
    $MLEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

    4 - Atreca, Inc. (0001532346) (Issuer)

    4/17/24 7:36:28 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    12/18/23 4:15:16 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Moolec Science with a new price target

    ROTH MKM initiated coverage of Moolec Science with a rating of Buy and set a new price target of $5.00

    9/27/23 7:44:02 AM ET
    $MLEC
    Blank Checks
    Finance

    Stifel reiterated coverage on Atreca with a new price target

    Stifel reiterated coverage of Atreca with a rating of Buy and set a new price target of $14.00 from $17.00 previously

    3/4/22 7:37:56 AM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

    Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

    9/15/21 7:48:59 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CMND
    $MLEC
    Leadership Updates

    Live Leadership Updates

    View All

    Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

    Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the fir

    11/13/25 8:54:39 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

    Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Cl

    10/27/25 9:22:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BCEL
    $CMND
    $MLEC
    Financials

    Live finance-specific insights

    View All

    180 Life Sciences Corp. - Corporate Updates

    Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

    10/3/24 8:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moolec Science Presents Fiscal Year 2024 Annual Business Update

    LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge. Also, Moolec made significant advancements in both upstream and downstream processes.Piggy Sooy™: Field trials in three different US locations continue on sch

    10/2/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

    LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.The Conference Call will be accompanied by a pr

    9/25/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    $ATNF
    $BCEL
    $CMND
    $MLEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clearmind Medicine Inc.

    SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)

    11/14/24 5:08:52 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Spectaire Holdings Inc.

    SC 13G/A - Spectaire Holdings Inc. (0001844149) (Subject)

    11/14/24 1:45:01 PM ET
    $SPEC
    Industrial Machinery/Components
    Industrials